Skip to main content
Sister Publication Links
  • ESG: THE NEW IMPERATIVE
Subscribe
  • My Account
  • Login
  • Subscribe
  • News
    • Current News
    • COVID-19
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Transformation
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Digital Health
  • Insights
    • ACA 10 Years After
    • Best Practices
    • Special Reports
    • Innovations
  • Data/Lists
    • Rankings/Lists
    • Interactive Databases
    • Data Points
  • Op-Ed
    • Bold Moves
    • Breaking Bias
    • Commentaries
    • Letters
    • Vital Signs Blog
    • From the Editor
  • Awards
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top 25 Innovators
    • Diversity in Healthcare
    • Women in Healthcare
    • - Luminaries
    • - Top 25 Diversity Leaders
    • - Leaders to Watch
    • - Luminaries
    • - Top 25 Women Leaders
    • - Women to Watch
  • Events
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Custom Media Event: ESG Summit
    • Transformation Summit
    • Women Leaders in Healthcare Conference
    • Social Determinants of Health Symposium
    • Leadership Symposium
    • Health Care Hall of Fame Gala
    • Top 25 Women Leaders Gala
    • Best Places to Work Awards Gala
    • Top 25 Diversity Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Supply Chain Revenue Cycle
    • - Hospital at Home
    • - Workplace of the Future
    • - Strategic Marketing
    • - Virtual Health
  • Listen
    • Podcast - Next Up
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Video Series - The Check Up
    • Sponsored Video Series - One on One
  • MORE +
    • Advertise
    • Media Kit
    • Newsletters
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Government
May 02, 2015 01:00 AM

Beware a 21st Century Quackery Act

Merrill Goozner
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print
    Goozner

    Proposed legislation “modernizing” the Food and Drug Administration's approach to approving breakthrough drugs and devices would undermine the agency's ability to protect the American public from unproven and possibly unsafe new products.

    The so-called 21st Century Cures Act also contains sections that would hamstring healthcare providers and insurers in their efforts to lower the cost of care. Unless the legislation is sharply revised, it should be rejected by Congress or, if need be, vetoed by the president.

    To gain bipartisan support, the drafters of the bill included more money for the National Institutes of Health and a new role for patient-reported outcomes. Those are laudable goals—especially the boost for basic science research, which is the foundation of innovation in medicine.

    But there was no need to simultaneously degrade the scientific basis of new drug and device approvals; allow Congress to impose its own rules for what constitutes acceptable medical evidence; or weaken the standards for protecting human subjects in clinical trials—all of which is in the bill.

    For no apparent reason, the legislation also imposes new disclosure requirements on hospitals and insurance companies when they create preferred drug lists or formularies, which enable substitution of lower-priced, comparable products. It also absolves the industry from having to disclose payments to doctors for attending continuing medical education run by a third party they've funded.

    Those two provisions are not about coming up with new cures. They are designed to give drug and device companies more freedom to market the less effective and more expensive cures they already have.

    But even if the bill were stripped of those extraneous provisions, providers and insurers have a huge stake in understanding how the regulatory standards included in this legislation would pose a grave threat to the government oversight process.

    Since 1962, the FDA has required manufacturers to test their new products in randomized clinical trials comparing the actual clinical outcomes in two comparable groups, only one of which received the drug. Sometimes products that affect surrogate biomarkers such as high cholesterol or high blood pressure—neither of which is a disease—get approved. But they must conduct clinical trials that definitively show that a drug affecting those biomarkers leads to clinically meaningful outcomes, which in those cases means reducing heart attacks and strokes.

    In place of that tried-and-true scientific method, Congress would substitute a new standard for drugs to treat life-threatening diseases such as cancer, where hope for new breakthroughs these days lies in targeting the tumors' mutated genes or their protein expressions. Those are biomarkers, and under the legislation, manufacturers could get accelerated approval from the FDA if the tested molecule had an effect on a biomarker that is “reasonably likely to predict clinical benefit.”

    Do we really want a “reasonably likely” standard to determine if the healthcare system should pay $10,000 a month per patient for the next new cancer drug?

    The bill also requires the FDA to create a pathway where manufacturers could submit “evidence from clinical experience”—observational trials, registries or case reports—to support expanded uses of already-approved drugs.

    Devicemakers get a similarly easy path for a new “breakthrough” device designation. Instead of controlled trials, they could submit case histories, registry data or studies published in peer-reviewed journals. If they provide the latter, the FDA would have to submit a written request for the underlying data. If those data weren't available, the agency still would have to consider the study.

    Patients volunteering for clinical trials will want to be on guard should the legislation pass. Waivers to the informed-consent requirement have always been allowed when it is not feasible to obtain consent. The bill would add another exception: when “the proposed clinical testing poses no more than minimal risk.”

    Even if the risk is minimal, why would the authors of this legislation waive a central tenet of international agreements designed to protect the rights of human subjects in clinical trials?

    In her final address last month as FDA commissioner, Dr. Margaret Hamburg wisely noted that “innovation doesn't matter if the product doesn't work ... It is foolish—in fact dangerous—to believe that reducing regulatory standards will make new treatment interventions appear if the science is not there.”

    Rep. Fred Upton (R-Mich.) and Rep. Diana DeGette (D-Colo.), the bill's sponsors, should heed her warning. Back to the drawing board on the 21st Century Cures Act.

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    Dr. Anthony Fauci
    Fauci: 'Pandemic phase' over for US, but COVID-19 still here
    greenhouse emission
    5 takeaways from HHS' environmental justice strategy
    Sponsored Content
    Modern Healthcare Alert: Sign up for this breaking news email to be kept in the loop as urgent healthcare business news unfolds.
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Advertise with Us
    • Ad Choices Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2022. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • COVID-19
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Digital Health
    • Insights
      • ACA 10 Years After
      • Best Practices
      • Special Reports
      • Innovations
    • Data/Lists
      • Rankings/Lists
      • Interactive Databases
      • Data Points
    • Op-Ed
      • Bold Moves
      • Breaking Bias
      • Commentaries
      • Letters
      • Vital Signs Blog
      • From the Editor
    • Awards
      • Nominate/Eligibility
      • 100 Most Influential People
      • 50 Most Influential Clinical Executives
      • Best Places to Work in Healthcare
      • Excellence in Governance
      • Health Care Hall of Fame
      • Healthcare Marketing Impact Awards
      • Top 25 Emerging Leaders
      • Top 25 Innovators
      • Diversity in Healthcare
        • - Luminaries
        • - Top 25 Diversity Leaders
        • - Leaders to Watch
      • Women in Healthcare
        • - Luminaries
        • - Top 25 Women Leaders
        • - Women to Watch
    • Events
      • Conferences
        • Transformation Summit
        • Women Leaders in Healthcare Conference
        • Social Determinants of Health Symposium
        • Leadership Symposium
      • Galas
        • Health Care Hall of Fame Gala
        • Top 25 Women Leaders Gala
        • Best Places to Work Awards Gala
        • Top 25 Diversity Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Supply Chain Revenue Cycle
        • - Hospital at Home
        • - Workplace of the Future
        • - Strategic Marketing
        • - Virtual Health
      • Webinars
      • Custom Media Event: ESG Summit
    • Listen
      • Podcast - Next Up
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Video Series - The Check Up
      • Sponsored Video Series - One on One
    • MORE +
      • Advertise
      • Media Kit
      • Newsletters
      • Jobs
      • People on the Move
      • Reprints & Licensing